CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A011401 | Alliance | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GU008 | NRG | Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
| E1A11 | ECOG | Randomized Phase III Trial of Bortezomib; LENalidomide and Dexamethasone (VRd) Versus Carfilzomib; Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S0124 | SWOG | Randomized Phase III Trial of Cisplatin (NSC-119875) and Irinotecan (NCSC-616348) Versus Cisplatin and Etoposide (NSC-141540) in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC) | Adult CIRB - Late Phase Emphasis | Completed |
| E1A05 | ECOG | Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) - Lenalidomide (Revlimid) - Dexamethasone (VRD) versus Bortezomib (Velcade) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen | Adult CIRB - Late Phase Emphasis | Completed |
| GOG-0209 | GOG | Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| E3A06 | ECOG | Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA5181 | ECOG-ACRIN | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
| A022102 | Alliance | Randomized Phase III trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| N0949 | NCCTG | Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer | Adult CIRB - Late Phase Emphasis | Completed |